Company Focus
Ipsen
Latest Ipsen News
Biotechnology
French biotech Ipsen has entered an exclusive global licensing agreement with Biomunex Pharmaceuticals to develop BMX-502, a first-in-class T cell engager. 3 December 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Latest News & Features of interest to Ipsen
Pharmaceutical
Italy-based CNS specialist Newron Pharmaceuticals has entered into a license agreement with EA Pharma, part of Japan’s Eisai to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated territories. 13 December 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). 13 December 2024
Pharmaceutical
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
Biotechnology
US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial. 12 December 2024
Pharmaceutical
A plan to buy back a whopping $15 billion worth of shares comes in at three times the previous largest scheme in Eli Lilly’s history. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Pharmaceutical
UK-based Essential Pharma has announced the completion of a 900 million euros ($945 million) financing. 12 December 2024
Biotechnology
Daiichi Sankyo has announced plans to invest 1.1 billion renminbi ($150 million) to build a new manufacturing facility for antibody-drug conjugates (ADCs) in Shanghai's Zhangjiang area. 12 December 2024
Pharmaceutical
Eli Lilly has announced Phase III results for imlunestrant, its investigational oral selective estrogen receptor degrader (SERD), in breast cancer. 12 December 2024
Latest In Brief for Ipsen
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Relevant Ones To Watch News
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
16 December 2024
16 December 2024
12 December 2024
5 December 2024
29 November 2024
26 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze